There's a relatively new cancer test that assesses the likelihood that breast cancer will recur and it can also provide information as to whether a patient will benefit chemotherapy. This called the Oncotype DX Test. The studies for this began in 2004, and after evaluating patients who took this test, it was found that about half the patients would not benefit from chemotherapy. Prior to this test, all patients would have been given chemo as a matter of course. This test is only effective for those patients that do not have lymph node involvement and whose cancer is hormone receptor positive. This type of breast cancer is the most common, so this test will benefit the most people. For more information, search the web using "Oncotype DX" for a plethora of articles.

< Prev		Next >